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Abstract
Background: Patients on the selective serotonergic reuptake inhibitors like citalopram report emotional blunting. We showed 
previously that citalopram reduces resting-state functional connectivity in healthy volunteers in a number of brain regions, 
including the dorso-medial prefrontal cortex, which may be related to its clinical effects. Bupropion is a dopaminergic and 
noradrenergic reuptake inhibitor and is not reported to cause emotional blunting. However, how bupropion affects resting-
state functional connectivity in healthy controls remains unknown.
Methods: Using a within-subjects, repeated-measures, double-blind, crossover design, we examined 17 healthy volunteers 
(9 female, 8 male). Volunteers received 7 days of bupropion (150 mg/d) and 7 days of placebo treatment and underwent resting-
state functional Magnetic Resonance Imaging. We selected seed regions in the salience network (amygdala and pregenual 
anterior cingulate cortex) and the central executive network (dorsal medial prefrontal cortex). Mood and anhedonia measures 
were also recorded and examined in relation to resting-state functional connectivity.
Results: Relative to placebo, bupropion increased resting-state functional connectivity in healthy volunteers between the 
dorsal medial prefrontal cortex seed region and the posterior cingulate cortex and the precuneus cortex, key parts of the 
default mode network.
Conclusions: These results are opposite to that which we found with 7 days treatment of citalopram in healthy volunteers. 
These results reflect a different mechanism of action of bupropion compared with selective serotonergic reuptake inhibitors. 
These results help explain the apparent lack of emotional blunting caused by bupropion in depressed patients.
Keywords: bupropion, antidepressant, resting-state, functional connectivity, depression
Introduction
Resting state functional connectivity (RSFC) has been found 
dysfunctional in patients with major depressive disorder (MDD) 
in networks such as the Salience Network (SN), the Central 
Executive Network (CEN), and the Default Mode Network (DMN) 
(Sheline et al., 2010).
The SN and the CEN are described as task-positive networks, 
activated during tasks and less active at rest in healthy con-
trols. The SN involving the anterior insula, pregenual anterior 
cingulate (pgACC) and amygdala is implicated in the processing 
of various aspects of salient stimuli, whereas the CEN, which 
consists of regions such as the dorsolateral, dorsal medial pre-
frontal cortex, and the posterior parietal cortex, is involved 
in cognitive functioning including attention and working 
memory (Bressler and Menon, 2010a). The DMN, more active 
at rest, involves brain regions such as the posterior cingulate 
cortex, precuneus cortex, and medial prefrontal cortex and is 
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implicated in self-referential activity and emotion regulation 
(Bressler and Menon, 2010b).
Abnormalities in these networks have been found in 
depressed patients and are thought to reflect difficulties with 
the suppression of unwanted thoughts, deficits in attentional 
control over emotional stimuli, and difficulties with emotion 
recognition. However there have been inconsistencies in lit-
erature regarding the direction of effects with some studies 
finding increased SN and CEN (Horn et al., 2010; Sheline et al., 
2010; Whitfield-Gabrieli and Ford, 2012; Manoliu et  al., 2014; 
Ramasubbu et al., 2014) whilst others find reduced connectivity 
(Ye et al., 2012; Tahmasian et al., 2013; Liston et al., 2014) in these 
regions in MDD. These inconsistencies might be related to het-
erogeneity in the MDD population studied and also differences 
in medication history. To combat problems with medication his-
tory, we recently examined young people with high depression 
symptomatology but no medication history. We examined seed 
regions in the SN and the CEN and found decreased RSFC in the 
symptomatic group between the amygdala and the pgACC and 
hippocampus and precuneus. We also found decreased RSFC in 
the symptomatic group between the pgACC and the putamen 
and between the dorso-medial prefrontal cortex (dmPFC) and 
the precuneus (Rzepa and McCabe, 2016). We thus suggest that 
networks such as the SN and CEN may be targets for normaliza-
tion with treatment.
Examining the effects of pharmacological treatments on neu-
ral processes, Fu et al. report that MDD patients showed increased 
connectivity in the anterior DMN with 12 weeks duloxetine 
(selective noradrenergic reuptake inhibitor) treatment (Fu et al., 
2015). However, it has recently been shown that 8 weeks treat-
ment of escitalopram (selective serotonergic reuptake inhibitors 
[SSRI]) significantly reduced dmPFC activity in MDD patients 
after treatment, which additionally correlated with depression 
symptom improvement (Wang et  al., 2015). The inconsisten-
cies may be related to the change in symptoms following treat-
ment. Thus, investigating the effects of antidepressants outside 
of mood changes is a useful first step in understanding their 
mechanism of action. We and others have examined the effects 
of 7 days treatment with SSRIs in healthy volunteers and found 
decreased functional connectivity between the prefrontal cortex 
and the DMN (McCabe and Mishor, 2011; McCabe et al., 2011; van 
de Ven et al., 2013) and decreased functional connectivity over 
many networks with just a single dose of an SSRI (Klaassens 
et al., 2015). Furthermore, 2 weeks of duloxetine (SNRI) was also 
found to reduce DMN and task positive network connectivity in 
healthy volunteers (van Wingen et al., 2014). Taken together, this 
suggests the direction of effects on the resting state may be dif-
ferent based on the mechanism of action of the antidepressants 
examined. Moreover, reports suggest that SSRIs can contrib-
ute to emotional blunting in patients, where experiences both 
positive and negative are flattened (Price et al., 2009), whereas 
catecholamine antidepressants like bupropion (dopamine and 
noradrenaline reuptake inhibitor) (Stahl et  al., 2004; Dwoskin 
et al., 2006) might be more efficacious at improving anhedonia 
in depression (Dunlop and Nemeroff, 2007; Nutt et  al., 2007; 
McCabe et al., 2009). In light of this, we recently examined the 
effects of 7  days treatment with bupropion and found, unlike 
with citalopram (SSRI), enhanced neural activity in healthy 
controls during the anticipation, effort, and consummation of 
rewarding and aversive stimuli (Dean et al., 2016). However, how 
bupropion affects RSFC remains as-yet unknown.
Thus, our current study is the first to investigate the effects 
of 7  days bupropion administration on the RSFC in healthy 
volunteers using a double-blind, placebo-controlled, crosso-
ver design. Based on previous literature, we selected regions 
of interest (ROIs) that have been shown to be dysfunctional in 
depression (amygdala, pgACC, and the dmPFC). We hypoth-
esized that bupropion, with its opposite effects to citalopram 
during our fMRI tasks, might also have opposite effects on RSFC 
compared with citalopram. That is, we expected that bupropion 
might increase RSFC, compared with the placebo control con-
dition, in line with our recent study showing increased neural 
activity under bupropion (Dean et al., 2016).
Methods and Materials
Participants
Seventeen healthy, right-handed, Caucasian volunteers (mean 
24 years, 9 female) were randomized to receive 7 days oral treat-
ment with bupropion (150  mg/d) and 7  days oral treatment 
with placebo separated by a 2-week washout phase in a dou-
ble-blind, within-subjects design. The study was located at the 
Centre for Neuroscience and Neurodynamics in the Department 
of Psychology at the University of Reading. Volunteers were 
recruited via advertisement and, after reading study infor-
mation, provided written consent prior to screening. Ethical 
approval was obtained from the University of Reading.
The exclusion criteria included current/previous psychi-
atric disorder (including alcohol or drug dependency) using 
the DSM-IV Structured Clinical Interview (First et al., 2002), 
pregnancy, and any contraindications to MRI and bupropion 
(including family history of bipolar disorder and seizures/epi-
lepsy). Volunteers were medication free for the past 3 months 
(excluding the contraceptive pill) before starting the study and 
underwent a physical examination. Volunteers had a healthy 
BMI, and their liking and craving for chocolate was measured 
using a questionnaire (Rolls and McCabe, 2007). Eleven volun-
teers were nonsmokers, 4 smoked <1 cigarette/wk, 1 smoked 
5 cigarettes/wk, and 1 smoked 1 to 2 cigarettes/d on average. 
Baseline measures of mood and anhedonia were taken using 
the Beck Depression Inventory (Beck et  al., 1961), Snaith-
Hamilton Pleasure Scale (Snaith et  al., 1995), Fawcett-Clarke 
Pleasure Capacity Scale (FCPS) (Fawcett et  al., 1983), Temporal 
Experience of Positive Mood (TEP) (Gard et  al., 2007), and 
Behavioral Inhibition/Activation Scales (BIS/BAS) (Carver and 
White, 1994). The BIS is hypothesized to be sensitive to cues of 
threat or punishment and is associated with avoidant or with-
drawal behaviors (Zinbarg and Lira Yoon, 2008; Bijttebier et al., 
2009). The BAS is hypothesized to be sensitive to cues of reward 
or appetite and is associated with approach behaviors (Fowles, 
1988). Given that we used taste stimuli, including chocolate, 
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volunteers also completed the Eating Attitudes Questionnaire 
(Garner et al., 1982) to assess eating attitudes.
Experimental Design
The study used a randomized, double blind, within-subjects, 
counterbalanced, crossover design. Volunteers received 7  days 
(1 tablet each morning) of bupropion treatment (150  mg/d) 
and 7 days of placebo treatment, separated by a 2-week wash-
out phase. Treatment order was randomized, with 9 volun-
teers receiving bupropion first and 8 receiving placebo first. 
Volunteers underwent an fMRI scan on the 7th day of each treat-
ment at approximately 3 hours after last dose. One volunteer 
had a scan after 6  days treatment (drug) due to experiencing 
adverse side-effects. Medication was provided by the Oxford 
Health NHS Foundation Trust and the Royal Free London NHS 
Foundation Trust. Participants were allowed only one caffein-
ated drink on the scan morning. Before scans, volunteers com-
pleted the Patient Rated Inventory of Side Effects (Sequenced 
Treatment Alternatives to Relieve Depression) to record any 
adverse side-effects. Mood was measured before and after scans 
using the befindlichkeit scale of mood and energy (von Zerssen 
et al., 1974) and a mood visual analogue scale (VAS).
MRI-derived measures of brain function, based on blood-
oxygenation-level-dependent (BOLD) contrast, were used 
to compare brain responses at rest in the treatment and the 
placebo groups. The resting-state data were acquired before 
any other scans, including the structural scan. Subjects were 
instructed to lie in dimmed light with their eyes open, think 
of nothing in particular, and not to fall asleep, similar to our 
previous studies (McCabe and Mishor, 2011; McCabe et al., 2011; 
Cowdrey et al., 2012; Rzepa et al., 2015; Rzepa and McCabe, 
2016) and a method found to have higher reliability than eyes 
closed (Patriat R et al., 2013).
Image Acquisition
A Siemens Magnetom Trio 3T whole body MRI scanner and a 
32-channel head coil were used. Multi-band accelerated echo 
planar imaging sequencing (Center for Magnetic Resonance 
Research) was used with an acceleration factor of 6 and iPAT 
acceleration factor of 2. T2*-weighted EPI slices were obtained 
every 0.7 seconds (TR = 0.7, TE = 0.03), these parameters were 
optimized given our scanner capability and used to increase 
sampling rates and increase our power to detect resting state 
networks as has been shown previously with multiband (Xu 
et  al., 2013) (Filippini et  al., 2014). Fifty-four transverse slices 
with in-plane resolution of 2.4 x 2.4mm were attained and slice 
thickness was 2.4 mm. The matrix size was 96 x 96 and the field 
of view were 230 x 230 mm. Acquisition was performed during 
resting-state scan, yielding 400 volumes in total. Sagittal 3D 
MPRAGE images were also acquired with an isotropic in-plane 
resolution of 1 x 1 x 1 (TI = 0.9 seconds, TR = 2.02, flip angle 9°, 
FOV = 250 x 250 mm) yielding 192 slices.
fMRI Data Analysis
Preprocessing
Imaging data were preprocessed and analyzed using FSL tools 
(www.fmrib.ox.ac.uk/fsl) (Smith et  al., 2004). fMRI data pre-
processing was carried out using FEAT (FMRI Expert Analysis 
Tool, version 6.0, a part of FSL software) and included the 
following steps: non-brain removal (Smith, 2002), motion 
correction using MCFLIRT (Jenkinson and Smith, 2001), 
spatial smoothing using a Gaussian kernel of full-width at 
half maximum of 5  mm, grand mean intensity normaliza-
tion of the entire 4D dataset by a single multiplicative factor, 
and high pass temporal filtering (Gaussian-weighted least-
squares straight line fitting, with sigma = 64.0  s). fMRI vol-
umes were registered to the individual’s structural scan and 
the MNI-152 standard space image (Montreal Neurological 
Institute, Montreal, QC, Canada) using FMRIB’s Linear Image 
Registration Tool (Jenkinson et al., 2001).
Time Series Extraction and Higher Level Analysis
To study RSFC, a seed-based correlation approach was used. 
Using the Harvard-Oxford subcortical structural atlas (Kennedy 
et al., 1998), we created a structural bilateral amygdala. To maxi-
mize the exact coverage, the masks of these seed regions were 
threshold by 20% to include voxels having at least 80% of prob-
ability of being in these particular regions. We also created seeds 
for the dmPFC (18 34 29; -24 35 28, 6-mm sphere) coordinates 
from (Sheline et al., 2010) and a pgACC seed (0 38 0, 8 mm sphere) 
coordinates from the center of the region in the Harvard-Oxford 
Structural atlas. Spheres were checked that they did not cross 
into other brain regions. The seeds were created with Wake 
Forest University Pickatlas tool in SPM8 similar to our recent 
paper (Rzepa and McCabe, 2016) and our previous RSFC paper 
with citalopram (McCabe et al., 2011).
The mean time course within the left and right seeds of 
each ROI (except for the pgACC, only comprising one medial 
seed) was calculated and used as a single regressor added to 
the general linear model. In addition, white matter signal, cer-
ebrospinal fluid signal, 6 motion parameters (3 translations 
and 3 rotations), and the global mean time-series over whole 
brain were used as nuisance regressors. We have obtained 
white matter and cerebrospinal fluid masks using FSL’s FAST 
segmentation program. The resulting segmented images were 
then thresholded to ensure 80% tissue type probability. For each 
individual, the general linear model was analysed by using the 
FMRI Expert Analysis Tool [version 5.4, part of FMRIB’s Software 
Library (Smith et al., 2004)]. The resulting parameter estimate 
maps were then analyzed using higher level 1-sample t tests for 
group averages and between-samples t tests for group differ-
ences. Images were corrected for multiple comparisons using 
clusters with Z > 2.3 voxel-wise thresholding and a family-wise 
error-corrected cluster significance threshold of P < .05 (Worsley, 
2001). We also included FSLs FLAME1, which also considers the 
variance of the subject-specific parameter estimates and has 
been found by Eklund et  al. (2016) to be a clusterwise infer-
ence that stands out as having much lower FWE, often being 
valid (<5%, i.e., reduced false positives) compared with other 
fMRI packages. From the results, we then only reported those 
that met the further correction for number of ROIs examined, 
which gave P < .016 (i.e., P < .05 Bonferroni corrected for the 3 
networks of interest: amygdala, dmPFC, and pgACC) (Davidson 
et al., 2003). The percent BOLD signal change in the graphs is the 
PE/COPE values converted to mean percent BOLD signal change 
via Featquery (FSL; www.fmrib.ox.ac.uk/fsl; Smith et al., 2004) 
for the regions that had significant correlations with the seeds 
(Table 2).
Correlational Analyses
To examine the relationship between the scores on behavioral 
questionnaires and RSFC, we extracted the percent BOLD signal 
change using FSL Featquery and correlated with scores on the 
following questionnaires: FCPS, BIS/BAS, and TEPS.
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Results
Demographic Details and Mood Ratings
Demographic data (Table  1) indicated that participants had 
low depression and anhedonia scores, as measured on range 
of mood and anhedonia questionnaires. A  repeated-meas-
ures ANOVA was performed to examine the effect of treat-
ment (bupropion/placebo) and time (pre-/postscan) on mood 
and affect, as measured by the BFS and VAS (supplementary 
Table  1). Results revealed that there was no significant effect 
of treatment [F(1,16) = .483, P = .497], time [F(1,16) = .822, P = .378], 
treatment by time [F(1,16) = 1.922, P = .185], treatment by VAS 
[F(1,16) = 2.472, P = .084] or treatment by time by VAS interac-
tions [F(1,16) = .689, P = .545]. There was also no significant effect 
of treatment [F(1,14) = 1.61, P = .225] or treatment by time inter-
action [F(1,14) = 2.176, P = .162] on total BFS scores. However, 
there was a significant main effect of time on overall BFS score 
[F(1,14) = 5.879, P = .029].
Adverse Effects
Supplementary table  2 reports the number of adverse effects 
experienced on each treatment, as measured on the Patient 
Rated Inventory of Side Effects. The most commonly reported 
adverse effects across both treatment phases were headache 
(n = 5 per treatment), difficulty sleeping (n = 3 per treatment), 
and fatigue (n = 3 placebo, n = 5 bupropion). Dizziness (n = 4) was 
the most commonly reported adverse effect in the bupropion 
condition that was not reported in the placebo condition.
Main Effects of Stimuli on Blood Oxygen Level-
Dependent Responses
Supplementary Tables 3 and 4 provide a summary of main effect 
of 1-sample t test on seed ROI functional connectivity (baseline) 
for the placebo and bupropion. Overall, the patterns of connec-
tivity associated with each of the seed regions are consistent 
with resting-state functional connectivity experiments inves-
tigating effects of antidepressants in healthy individuals and 
depressed patients (Lai and Wu, 2012; Li et al., 2013; Posner et al., 
2013; Wang et al., 2014, 2015; Shen et al., 2015; Sikora et al., 2016).
Within-Subjects Analysis Examining the Treatment  
Effect
Right dmPFC Seed
There was increased RSFC between the right dmPFC seed and 
the right posterior cingulate (Table 2; Figure 1) and precuneus 
cortex in the bupropion group compared with the placebo 
group. Both these results survived the correction for the number 
of seeds examined (P < .016; Bonferroni corrected for multiple 
comparisons). We also found increased functional connectivity 
between the left dmPFC seed region and the precuneus (-4 -46 
48, P < .0394), yet this did not survive the multiple comparisons 
Bonferroni correction for the number of seeds examined.
Correlations with Behavioral Measures
We found a negative correlation between the decreased RSFC of 
the dmPFC seed and the precuneus and increased BIS under the 
drug condition (r = -.494, P = .044; however, this did not survive 
multiple correction for the number of questionnaires examined) 
and no correlation in the placebo condition (r = .404, P = .108).
We also found a negative correlation between decreased 
RSFC of the dmPFC seed and the precuneus and decreased 
behavioral activation subtype of fun (BAS fun) under the placebo 
condition (r = -.578, P = .015; this also survived multiple correc-
tion for the number of questionnaires) but no correlation in the 
drug condition (r = .239, P = .355) (Figure 2). We also examined the 
difference in these correlations with the Fishers r to z transfor-
mation and found z = -2.68, P < .007 (2-tailed). This means that 
there was decreased connectivity in the placebo group as levels 
of fun reported decreased.
Discussion
The main aim of our study was to investigate the effects of 
7 days bupropion treatment on RSFC in healthy volunteers. Our 
previous work found that the serotonin reuptake inhibitor cit-
alopram reduced not only the brain’s activity during reward and 
aversive processing but also reduced RSFC (McCabe et al., 2010, 
2011; McCabe and Mishor, 2011). We suggested that this profile 
of action might be related to citalopram’s positive clinical effects 
but perhaps also emotional blunting. Drugs like bupropion, 
which are dopaminergic noradrenergic reuptake inhibitors, are 
thought less likely to cause emotional blunting. In keeping with 
this notion, we have recently shown that bupropion (unlike cit-
alopram) can increase the brain’s activity during the process-
ing of positive and negative stimulation (Dean et  al., 2016). 
Therefore, we hypothesized that perhaps bupropion would also 
increase the brain’s RSFC in key regions such as the dmPFC that 
we found modulated by citalopram (McCabe et al., 2011).
Table 2. Resting State Functional Connectivity for the dmPFC Seed 
Region
MNI coordinates
Brain Region X Y Z
Cluster  
size z-Score P value
dmPFC seed
bupropion > placebo
PCC
Precuneus
4
8
-40
-58
14
32
449
449
3.47
3.1
<0.001
<0.001
P values cluster corrected family wise error P < .05, further corrected for  
multiple comparisons across 3 seed networks resulting in P = .016.
PCC, posterior cingulate cortex.
Table 1. Group Demographic and Psychosocial Measures
Measure
Age (y) 24 (4.26)
Ethnicity 100% Caucasian
BMI 23.29 (2.38)
BDI 1.71 (3.14)
FCPS 136.76 (14.48)
SHAPS 20.65 (5.67)
TEPS anticipatory 47.53 (7.75)
TEPS consummatory 37.59 (4.95)
BAS drive 11.06 (2.49)
 Fun seeking 11.75 (3.11)
 Reward responsiveness 17.53 (1.87)
BIS 20.41 (4.24)
Abbreviations: BMI, Body Mass Index; BDI, Beck Depression Inventory; FCPS, 
Fawcett Clarke Pleasure Scale; SHAPS, Snaith-Hamilton Pleasure Scale; TEPS, 
Temporal Experience of Pleasure Scale; BAS/BIS, Behavioral Activation/Behavio-
ral Inhibition Scale.
Data are means (SD) except for ethnicity, which is percentage.
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 Our main findings revealed that bupropion increased RSFC 
between the dmPFC seed region and the PCC and between the 
dmPFC and the precuneus cortex compared with placebo. The 
dmPFC is implicated in many cognitive and emotional pro-
cesses, while the precuneus and the PCC are thought to be 
involved in self-referential and memory processes (Bressler and 
Menon, 2010b; Jaworska et al., 2015; Janssen et al., 2015). Studies 
of RSFC in depressed patients have revealed abnormalities in 
similar regions (Abbott et al., 2013; Manoliu et al., 2013; Zhong et 
al., 2016), with the authors suggesting that these abnormalities 
might represent patients’ difficulty in disengaging from self-
referential processes, which might lead to increased negative 
thoughts (Manoliu et al., 2013). Furthermore, van Tol et al., 2014 
report decreased cortical thickness related to decreased RSFC 
between the dmPFC and the PCC/precuneus cortex in depressed 
patients. The authors suggest this might lead to maladap-
tive emotional regulation. Thus, our finding of increased RSFC 
between the dmPFC and the precuneus, key regions found dys-
functional in depression, might help explain the mechanism of 
action of treatments like bupropion. Moreover, we also found 
that our results are consistent with our previous data in young, 
unmedicated participants with depression symptoms that 
revealed reduced functional connectivity between the dmPFC 
and the precuneus (Rzepa and McCabe, 2016). Having found 
the same functional connectivity now increased under the 
bupropion condition suggests that perhaps these networks are 
involved in the putative mechanism of action of bupropion. 
Further studies should clarify this in depressed patients before 
and after treatment.
Interestingly, we also found a relationship between the BIS 
and the dmPFC precuneus RSFC in the bupropion group and the 
BAS in the placebo group. The BIS is hypothesized to be sen-
sitive to cues of threat or punishment and is associated with 
avoidant or withdrawal behaviors (Zinbarg and Lira Yoon, 2008; 
Bijttebier et al., 2009). The BAS is hypothesized to be sensitive 
to cues of reward or appetite and is associated with approach 
behaviors (Fowles, 1988). Studies in depressed patients have 
shown high levels of BIS activation and lower levels of BAS acti-
vation (Fowles, 1988; Gray, 1994; Davidson, 1998;Meyer et  al., 
2001; Kasch et al., 2002; Johnson et al., 2003; Campbell-Sills et al., 
2004; Pinto-Meza et al., 2006).
In this study, we found increased RSFC under the drug con-
dition (between the dmPFC and the precuneus) that correlated 
with reduced behavioral inhibition scores. However, this result 
did not survive the further Bonferroni correction for the num-
ber of questionnaires examined. Nonetheless, we believe it 
would be of interest to examine in future larger studies how 
bupropion might affect the avoidance of negative information. 
Interestingly though, a recent study examining internet gam-
ing addiction found that 6 weeks of bupropion treatment had a 
greater improvement on BIS scores than the SSRI escitalopram 
(Song et al., 2016).
As mentioned above, we also found that as RSFC under the 
placebo condition was increased (between the dmPFC and the 
precuneus), behavioral activation (Fun) levels were also higher. 
This result suggests that increased RSFC between these regions 
is correlated with increased feelings of pleasure and supports 
the notion that increasing connectivity under bupropion would 
be unlikely to cause emotional blunting (the flattening of emo-
tional experiences). However, as there was no significant effect 
under the bupropion condition, this is purely speculative and 
would need to be examined with a larger sample size in healthy 
Figure 1. (A) Resting state functional connectivity (RSFC) between the right dorso-medial prefrontal cortex (dmPFC) seed region (yellow) and the posterior cingulate 
cortex, higher in the bupropion treatment than the placebo treatment (green) overlaid on the Default Mode Network (DMN). (B) Percent BOLD signal change extracted 
for both of the groups.
Figure  2. Decreased Resting state functional connectivity (RSFC) between the 
dorso-medial prefrontal cortex (dmPFC) region and the precuneous correlates 
with decreasing Behavioral Activation Scale (BAS) fun scores under placebo only.
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volunteers and then again in a depressed patient sample both 
before and after treatment.
Taken together, our results find that bupropion increases 
RSFC between the dmPFC seed region and the posterior cingu-
late cortex and the precuneus. The RSFC with the precuneus 
also correlates with increased experience of fun in the placebo 
condition. The RSFC results are opposite to that which we found 
previously with citalopram using similar methodology and seed 
regions and opposite to that found in young unmedicated peo-
ple with depression symptoms. Thus, our results may indicate a 
mechanism by which bupropion might work as an antidepres-
sant by increasing dmPFC RSFC.
Supplementary Material
Supplementary data are available at International Journal of 
Neuropsychopharmacology online.
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